Company intelligence / Profile preview

Cordlife

Ownership: Private
Development stage: Other

Overview

Cordlife operates Asia’s largest network of private cord blood banks with full processing and storage facilities in six key Asian markets. The company has released over seventy-seven cord blood units and twenty-one cord lining units to support transplants and infusions across ten countries. Clinical results include successful use of autologous and allogeneic transplants for conditions such as neuroblastoma and hypoxic ischemic encephalopathy. The company’s facilities are accredited by AABB.

Therapeutic areas: HematologyNeurologyOncologyOther
Modalities: Cell therapy (cord blood stem cells)Cell therapy (mesenchymal stromal cells)Cell therapy (epithelial stem cells)
Industry: Molecular Diagnostics

Partnerships

None specifically listed; indirect stake in Thai StemLife via subsidiary.

Beyond the preview

Go deeper on Cordlife.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cordlife.

Explore the full profile